Peking University Cancer Hospital & Institute: Carcinoma trials

The registry lists 15 Carcinoma studies with Peking University Cancer Hospital & Institute as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 11Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell CarcinomaNot yet recruitingNCT06472895Phase 1/2
• Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCCRecruitingNCT06360042Phase 2
• Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct CarcinomaRecruitingNCT06211114Phase 2
• Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCCRecruitingNCT05917431Phase 2
• HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell CarcinomaCompletedNCT06184841Phase 1
• The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular CarcinomaStatus unknownNCT05862181
• TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCCStatus unknownNCT04597970Phase 2
• Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT04479527Phase 2
• Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal LesionsStatus unknownNCT04170257Not applicable
• Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After ResectionStatus unknownNCT02767375Phase 2/3
• A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma PatientsStatus unknownNCT02727309Phase 1/2
• A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.Status unknownNCT02398552Phase 2
• Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer PatientsStatus unknownNCT02330783Phase 2
• DNA Methylation Biomarkers and Metastasis of Gastric CarcinomaCompletedNCT02159339
• Sorafenib Combined With Chemotherapy for Renal Collecting Duct CarcinomaCompletedNCT01762150Phase 2